Loading
Gene Expression and Cancer Classification · Journal article
Frontiers in Systems Biology · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a computational framework that uses gene regulatory networks inferred from TCGA expression data to propose NT-genes as candidate targets for cancer phenotype reversal. The authors predict that high-frequency NT-genes could simultaneously deactivate tumor cascades and reactivate normal programs, with theoretical unreached fractions varying by cancer type (≈6% in LUAD, ≈30% in PRAD). The work is entirely predictive and has no experimental, cell-based, animal, or clinical validation.
Computational modelling study using gene regulatory network inference. TCGA bulk RNA-Seq samples from five cancer types (including PRAD and LUAD); no living subjects enrolled or treated.. Intervention: Computational prediction of effects of targeting NT-genes, pure T-genes, or pure N-genes using quantitative and dynamical models. Compared with: Comparison of predicted intervention effects across gene categories (NT-genes versus pure T-genes versus pure N-genes) and across cancer types. Retrospective analysis of publicly available The Cancer Genome Atlas (TCGA) data; no specific clinical sites involved..
High-frequency NT-genes are predicted to simultaneously deactivate T-cascades and reactivate N-programs, in contrast to pure T-gene or N-gene interventions alone Unreached fraction U varies across cancers: approximately 30% in PRAD but only approximately 6% in LUAD under perfect diagnostic panels The framework yields testable predictions for intervention outcomes across cancer types based on composed coverage and unreached fraction metrics
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This framework is currently hypothesis-generating and does not support clinical decisions. Practitioners should view these predictions as computational leads requiring experimental validation in cell models, animal models, and ultimately clinical testing before consideration for therapeutic development.
This is a computational modelling study that raises mechanistic questions about gene network targets for cancer reversal, but provides no experimental validation, clinical data, or empirical evidence of efficacy in any biological system.
As stated by the source record.
Quoted from the source exactly as published.
This framework is currently hypothesis-generating and does not support clinical decisions. Practitioners should view these predictions as computational leads requiring experimental validation in cell models, animal models, and ultimately clinical testing before consideration for therapeutic development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Reversing the tumor phenotype is a long-standing challenge in cancer biology. Although GRNs comprise thousands of genes, normal and tumor tissues occupy distinct, low-dimensional attractors in expression space, raising the possibility that targeting a few key genes could induce widespread transcriptional changes. We build on two previously developed concepts: 1) N- and T-markers (genes with exclusive expression intervals in normal or tumor samples, respectively), and 2) Gene Deregulation Networks (GDNs) – directed acyclic graphs inferred from expression data, in which a link from C to E indicates that a deregulation at C increases the probability of a deregulation at E. A subset of N and T-genes, namely, NT-markers, appear in both networks and may act as bridges for phenotype reversal. Methods Using TCGA bulk RNA-Seq data from five cancer types we identified N-, T- and NT-genes based on statistically significant exclusive expression intervals. Discretized expression states (N-active, T-active, inactive) are then associated with normal-exclusive, tumor-exclusive and non-exclusive expression intervals. GDNs were constructed with the CChains algorithm using the Loevinger coefficient, followed by Reichenbach (common cause) and Mokken (transitivity) pruning. We introduced a quantitative model to predict intervention outcomes in a tumor using gene activation frequencies and two topological metrics: the composed coverage and the fraction of the T-network unreached by the reverse deactivation cascade (U). We also use a Glauber-like dynamical model to simulate interventions. Results We predict that pure T-gene interventions mainly alter the T-network, while pure N-gene interventions create a mixed normal-tumor state. In contrast, high-frequency NT-genes are predicted to simultaneously deactivate T-cascades and reactivate N-programs. The unreached fraction U varies across cancers: for perfect diagnostic panels, U ≈ 30% in PRAD but only ≈6% in LUAD. Escape probability also depends on tumor stage and on the spontaneous activation rate. Conclusion NT-genes with high dual frequency are predicted optimal targets for partial phenotype reversal. The combination of composed coverage, unreached fraction and normal-state relevance provides a quantitative guide for designing multi-target therapies. The framework is general and yields testable predictions for intervention outcomes across cancer types.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.